


Pharmacology Breakout
Grande Ballroom, The Scottsdale Plaza Resort

PHARMACOLOGY CONTENT



Select presentations will contain pharmacology content as noted in the program. Identified presentations represent approximately 3.25 hours of pharmacology content.

Friday, February 15, 2019	
<p>1:00 p.m.</p>	<p>Novel Anticoagulants Jeffrey A. Betcher, R.Ph.</p> <p>Objectives:</p> <ul style="list-style-type: none"> • Describe the role of novel anticoagulants (NOACs) • Classify drug-drug interactions of the available NOACs • Describe strategies to minimize procedural bleeding risks from the NOACs • Identify current options for urgent reversal of the NOACs
<p>1:50 p.m.</p>	<p>Update in Antibiotics Diane Rhee, Pharm.D., M.H.A.</p> <p>Objectives:</p> <ul style="list-style-type: none"> • Review current guideline-based duration of therapy for common infectious diseases • Understand the place in therapy for the most recently approved antibiotics <ul style="list-style-type: none"> ○ Ceftolozane/tazobactam (Zerbaxa®) 12/2014 ○ Ceftazidime/avibactam (Avycaz®) 2/2015 ○ Delafloxacin (Baxdela®) 6/2017 ○ Meropenem/vaborbactam (Vabomere®) 8/2017 ○ Plazomicin (Zemdri®) 6/2018 ○ Eravacycline (Xerava®) 8/2018 ○ Omadacycline (Nuzyra®) 10/2018 • Know the potential adverse effects and which patient/infection-specific factors would warrant use of these antibiotics
<p>2:40 p.m.</p>	<p>Refreshment Break</p>
<p>3:00 p.m.</p>	<p>Psychiatric Medication Challenges in the Medical Setting Robert P. Bright, M.D.</p> <p>Objectives:</p> <ul style="list-style-type: none"> • Identify factors influencing the choice of psychotropic medications in a patient with complex medical comorbidities • List medications that would be safest to use for agitation or depression in a patient with QTc prolongation • Describe the management of patients with anxiety in the medical setting

<p>3:50 p.m.</p> 	<p>Pharmacogenomics Christopher B. Grilli, Pharm.D., R.Ph. Objectives:</p> <ul style="list-style-type: none">• Discuss the role of CYP3A5 in solid organ transplant.• Review a patient case discussing necessary decision points for evaluating post-transplant pharmacogenomics.• Discuss potential limitations of pharmacogenomics within the transplant population.• Review pharmacogenomics of commonly used pain medications.
<p>4:40 p.m.</p>	<p>Workshop Adjourns</p>